In a significant pharmaceutical patent ruling, the U.S. Court of Appeals for the Federal Circuit reversed the lower court’s decision in Case No. 24-1061, involving Allergan, Janssen Pharmaceutica N.V., and affiliated entities as plaintiffs against MSN Laboratories Private Ltd. and Sun Pharmaceutical Industries Limited. Filed on October 18, 2023, and closed on August 13, 2024, the appeal centered on five U.S. patents covering eluxadoline formulations—the active ingredient in Viberzi®, a treatment for irritable bowel syndrome with diarrhea. The Federal Circuit’s reversal and remand fundamentally alters the litigation posture of all parties.

This case carries substantial strategic weight for branded pharmaceutical companies defending drug formulation patents against generic challengers. The Federal Circuit’s intervention signals potential flaws in the district court’s claim construction or infringement analysis, creating ripple effects for ANDA filers and innovator companies protecting blockbuster GI therapeutics. IP professionals, patent litigators, and R&D leaders in the pharmaceutical sector should closely examine this reversal as a case study in formulation patent vulnerability and appellate risk management.

Aperçu du dossier

Les parties

Les brevets en cause

The five patents at issue—US11160792B2, US11311516B2, US11229627B1, US11090291B2, and US11007179B2—cover formulations, compositions, and methods of use related to eluxadoline, the active pharmaceutical ingredient in Viberzi® (75 mg and 100 mg tablets). Eluxadoline is a mu-opioid receptor agonist and delta-opioid receptor antagonist used to treat irritable bowel syndrome with diarrhea (IBS-D) in adults. The patents protect specific tablet formulations, dosing regimens, and manufacturing characteristics that collectively define the branded product’s proprietary pharmaceutical profile.

• • US11160792B2
• • US11311516B2
• • US11229627B1
• • US11090291B2
• • US11007179B2

Représentation juridique

Plaintiff Counsel: O’Melveny & Myers LLP; Paul Hastings LLP (lead: Eric William Dittmann Esq.)
Defendant Counsel: Daignault Iyer LLP (lead: Richard Juang)

Chronologie du litige et historique de la procédure

This appeal was filed at the U.S. Court of Appeals for the Federal Circuit, the exclusive appellate venue for U.S. patent matters, indicating that an underlying district court had already issued a merits ruling on infringement that one or more parties found sufficiently problematic to appeal. The Federal Circuit’s docket reflects that this was a pure patent infringement action—most likely arising from Hatch-Waxman ANDA litigation, where brand manufacturers sue generic filers upon receipt of a Paragraph IV certification—and the appeal was routed through the Federal Circuit as the sole authority on patent law appeals from the regional circuits.

The case moved at a relatively efficient pace for Federal Circuit standards, with a 300-day duration from filing on October 18, 2023 to closure on August 13, 2024. The basis of termination was ‘Case Remanded,’ meaning the Federal Circuit did not itself resolve the underlying infringement dispute but instead identified reversible legal error in the lower proceeding and sent the case back for further proceedings consistent with its ruling. This outcome is procedurally significant: it avoids a final judgment for either party and prolongs the overall litigation timeline, likely extending uncertainty over generic market entry.

Le verdict et l'analyse juridique

Résultat

The Federal Circuit issued a reversal and remand, ordering the case returned to the originating forum for further proceedings. No final damages award or permanent injunction was entered at this appellate stage, as the court’s decision was limited to correcting a legal error identified below. The remand preserves the possibility of either an infringement finding or a non-infringement or invalidity finding on reconsideration, leaving the ultimate commercial outcome—including whether generic Viberzi® can enter the market—unresolved.

Analyse des causes du verdict

The Federal Circuit’s reversal in this infringement action most likely stems from one or more of the following legal grounds commonly associated with pharmaceutical patent appeals:

• Erroneous claim construction by the district court, where the lower tribunal may have interpreted one or more claim terms in the eluxadoline formulation patents too narrowly or too broadly, directly affecting the infringement analysis applied to MSN’s and Sun’s ANDA products.
• Improper application of the doctrine of equivalents or literal infringement standards, potentially misweighing how closely the defendants’ proposed generic formulations map to the asserted patent claims.
• Deficient or legally flawed analysis of objective indicia of non-obviousness or a related validity-adjacent issue that affected the infringement framework adopted at the trial level.
• Procedural or evidentiary error in the treatment of expert testimony or claim comparison evidence that the Federal Circuit determined materially affected the district court’s infringement determination.

Signification juridique

1. 1. The Federal Circuit’s decision to reverse and remand rather than affirm or render judgment signals a substantive legal error at the district court level, which may require a wholesale re-examination of how the eluxadoline patent claims are construed and applied—potentially reshaping claim construction standards for similar pharmaceutical formulation cases.
2. 2. For branded pharmaceutical companies relying on formulation patents to extend market exclusivity beyond a primary compound patent, this case reinforces that appellate review of ANDA-related infringement rulings remains an active and consequential strategic lever, with outcomes that can delay or accelerate generic entry.
3. 3. The involvement of five overlapping patents covering the same product (Viberzi® eluxadoline tablets) illustrates the layered patent protection strategy common in pharmaceutical portfolios; the remand outcome suggests that at least some of these patents survive appellate scrutiny sufficiently to warrant further district court consideration of infringement.

Points stratégiques à retenir

Pour les avocats spécialisés en brevets :

• When drafting formulation patent claims for pharmaceutical products, anticipate Federal Circuit claim construction scrutiny by using prosecution history to create a clear, well-defined claim scope that supports both literal and equivalents-based infringement theories.
• In ANDA patent litigation, appellate reversal and remand is a meaningful risk even after prevailing at the district court level; build briefing strategies around the Federal Circuit’s de novo review of claim construction from the outset of trial preparation.
• For multi-patent pharmaceutical cases like this one, coordinate claim construction positions across all asserted patents to avoid inconsistencies that could expose individual patent claims to reversal on different grounds.
• Monitor the remand proceedings closely, as the district court’s revised analysis under Federal Circuit guidance will likely clarify the precise infringement boundaries for eluxadoline formulations and set persuasive authority for future ANDA disputes in the GI therapeutic space.

Pour les professionnels de la propriété intellectuelle :

• Review your branded pharmaceutical patent portfolio for over-reliance on formulation patents that may face heightened claim construction vulnerability at the Federal Circuit, and consider supplementing with method-of-treatment or dosing regimen claims that are harder to design around.
• Track the remand proceedings in Allergan v. MSN Laboratories as a leading indicator of how courts will evaluate eluxadoline-related ANDA challenges going forward, and update freedom-to-operate analyses for any pipeline products using similar mu-opioid receptor modulation mechanisms.

Pour les équipes de R&D :

• If your R&D pipeline includes IBS-D treatments or opioid receptor-targeting therapeutics, the unresolved infringement status of the five eluxadoline patents means freedom-to-operate clearance in this space remains premature until the remand is resolved—prioritize monitoring the district court’s post-remand ruling.
• Consider investing in formulation differentiation strategies that move beyond eluxadoline’s protected dosage strengths and tablet compositions, as the Federal Circuit’s active engagement in this dispute signals these patents are substantively defensible and may survive the remand intact.